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Expression of human amyloid-b (Ab) in Drosophila is frequently used to investigate its toxicity
in vivo. We expressed Ab1–42 in the ﬂy using a secretion signal derived from the Drosophila necrotic
gene, as described in several previous publications. Surface-enhanced laser desorption/ionization
TOF MS analysis revealed that the Ab produced contained an additional glutamine residue at the
N-terminus. AbQ+1–42 was found to have increased protein abundance and to cause more severe neu-
rodegenerative effects than wild type Ab1–42 as assessed by locomotor activity and lifespan assays.
These data reveal that a commonly used model of Alzheimer’s disease generates incorrect Ab
peptide.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is characterized by the presence of
brain extracellular plaques rich in amyloid-b (Ab), a peptide
derived from the proteolytic cleavage of Amyloid-b Precursor Pro-
tein (AbPP) [1]. Differential processing of AbPP can produce several
different Ab species of varying lengths. Ab42 is signiﬁcantly more
cytotoxic than the abundant Ab40 normally found in healthy brains
[2,3] and the Ab42: Ab40 ratio is considered to be an important fac-
tor in neuronal health and AD progression [4,5].
When attempting to replicate AD-like neurodegeneration in the
vinegar ﬂy Drosophila, the need for AbPP processing has been cir-
cumvented by directly expressing Ab in ﬂy neuronal tissues [6–
8]. A secretory signal sequence at the N-terminus of the Ab peptide,
allowing its secretion from producing cells, was shown to be essen-
tial for inducing age-dependent phenotypes including reduced
adult lifespan [6,7], reduced locomotor activity [6,8], learning
defects [8], deposition of amyloid plaques [6,8] and visible brainand retinal degeneration [6–8]. This model system has since been
used to investigate the effect of single amino acid substitutions
in the Ab42 peptide sequence [6,9,10] and numerous other aspects
of AD including pharmacological [11] and genetic modiﬁcation
[12–20] of Ab-mediated toxicity.
We generated our own Ab42 expressing ﬂies, using the signal
peptide of the ﬂy necrotic gene to promote secretion of Ab as pre-
viously described [6,10,21–26]. We found that this Ab transgene
produced Ab42 with an additional glutamine residue at the N-ter-
minus. An alternative form of Ab42 generated from a construct with
the Drosophila Toll gene signal peptide is predicted to produce wild
type Ab42. We provide a comparison of the cytotoxicity and protein
abundance of these two Ab species.2. Materials and methods
2.1. Drosophila transgenic strains
As performed previously [27], the coding sequence for the Dro-
sophila Necrotic protein signal peptide (MASK-
VSILLLLTVHLLAAQFAQ) was cloned in front of the human Ab1–42
coding sequence to produce NSpAb1–42. A sequence encoding the
Fig. 1. Amyloid-b (Ab) peptide produced with the Necrotic signal peptide contains
an additional N-terminal glutamine. (A–D) SELDI-MS-TOF analysis of lysate from
the heads of adult ﬂies expressing NSpAb1–42 in all neurons under the control of
ElavGal4 (A and B) compared to control ﬂies with no Ab expression (C and D) using
two different antibodies: (A and C) WO2 (detects epitope 4–8 of Ab); and (B and D)
4G8 (detects epitope 17–21 of Ab). A peak of 4623 Da was detected in Ab ﬂies but
not control ﬂies. Monomeric Ab1–42 has a molecular weight of 4513 Da. The ﬁnal
residue of the Necrotic signal peptide, a glutamine, would account for the
discrepancy between expected and observed Ab1–42 molecular weights. (E–H)
SignalP 3.0 software was used to predict signal peptide cleavage site of Ab produced
with the Necrotic signal peptide (E and G) and the Toll signal peptide (F and H). (E)
NSpAb1–42 is predicted to be cleaved between residues 22 and 23 (highest Y-score
peak), resulting in Ab1–42 with an additional glutamine residue at the N-terminus
(G). The S-score indicates whether an amino acid is part of the signal peptide (high
score) or mature protein (low score). (F) Addition of the Toll signal peptide to the
Ab1–42 sequence is predicted to result in cleavage at residues 27 and 28, resulting in
production of the desired wild type Ab1–42 peptide (H).
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NSp to create the TSpAb1–42 construct. NSpAb1–42 and TSpAb1–42
were subcloned into: (1) the pUAST vector ([28], NSpAb1–42 only)
followed by injection into w1118 embryos; and (2) the pUAST-attB
vector ([29], both constructs) followed by injection into PhiC31 attP
96E and 86Fb strains. The ElavC155GAL4 (pan-neuronal expression)
and GmrGAL4 (expressed in all differentiated cells of the larval,
pupal and adult eye) lines are from the Bloomington Drosophila
Stock Centre.
2.2. Adult longevity assay
Groups of 20 male ﬂies (P8 replicates per genotype) raised at
29 C were collected within 72 h of eclosion. Vials were incubated
at 29 C and live ﬂies transferred to fresh food every 2–3 days. The
number of dead ﬂies was counted at each transfer. The survival
data was analysed and graphed using Kaplan–Meier log rank sur-
vival statistics in Prism Version 4.0c.
2.3. Negative geotaxis climbing assay
Flies were crossed, maintained and aged at 29 C. Ten male ﬂies
per replicate were placed in a Perspex vial, with markers at 2, 5,
and 8 cm dividing the vial into 4 height sections, each allocated a
value from 1 (lowest) to 4 (highest). Each vial was knocked ﬁrmly
onto the bench then photographed after 10 s. This was repeated 4
more times with 1 min rest intervals. The number of ﬂies in each
height section of each vial was averaged over the 5 photographs
then multiplied by the height section value. These weighted values
were ﬁnally added to calculate the ‘Climbing Score’ for each geno-
type. Flies were tested at 7-day intervals with P12 replicates for
each genotype at each age point. The data was analysed by two-
way ANOVA and Bonferroni post-hock test in Prism Version 4.0c.
2.4. Western blotting
20 adult heads per sample cut manually from the body were
homogenised in 2% SDS lysis buffer. Primary antibodies used:
W0-2 (detects residues 5–8 of human Ab) and alpha-tubulin
(Sigma). Blots were developed using ECL™ and recorded with a
Fujiﬁlm LAS-3000. Densitometric analysis was conducted using
MultiGauge software.
2.5. Surface-enhanced laser desorption/ionization (SELDI) TOF-MS
Heads from ElavC155-GAL4/Y; UAS-NSpAb1–42ori/+ adult ﬂies were
homogenised in lysis buffer containing 10 mM Tris–HCl pH 7.5 and
280 mM sucrose with anti-protease cocktail (Roche Diagnostics).
Samples were subjected to SELDI-TOF-MS as per [30].
2.6. Semi-quantitative PCR
Performed as described in [31] with mRNA extracted from 20
adult heads. Replicates were from independent biological samples.
Primers used: Actin42A (gcttcgctgtctactttcca, cagcccgactactgctt-
aga). Ab (ccgacatgactcaggatatgaa, gcccaccatgagtccaat).
3. Results
To generate a Drosophila model of Ab-mediated toxicity, UAS-
Ab1–42 expression constructs were made with the ﬂy Necrotic pro-
tein signal peptide (Sp) fused to the Ab1–42 peptide, termed
NSpAb1–42. Ectopic expression of NSpAb1–42ori in the developing
ﬂy eye resulted in rough eye phenotypes similar to those seen pre-
viously [6,7].To determine the predominant Ab species produced by our
NSpAb1–42ori over expression ﬂies, adult head lysate was subjected
to SELDI-TOF-MS. Two independent anti-Ab antibodies, W02 and
4G8, captured major peaks corresponding to molecular weights
of 4623.1 and 4623.9 Da respectively, slightly larger than the
expected Ab1–42 mass of 4515 Da (Fig. 1A and B). Examination of
the full-length, unprocessed NSpAb1–42 protein sequence revealed
a glutamine (Q) residue immediately N-terminal to the start of
the Ab1–42 sequence which would account for this additional mass.
SignalP3.0 signal peptide cleavage prediction software (http://
www.cbs.dtu.dk/services/SignalP-3.0/, [32]) predicted that
NSpAb1–42 is most likely to be cleaved at position 22/23 (Fig. 1E),
generating AbQ+1–42 (Fig. 1G) rather than the desired Ab1–42, sup-
porting our mass spectrometry data. In comparison, the Drosophila
Toll signal peptide (TSp) is predicted to cleave correctly when
fused to Ab1–42 (Fig. 1F and H).
New NSpAb1–42 and TSpAb1–42 transgenic constructs were gener-
ated, targeted to known genomic locations using the PhiC31 attP/
attB system [29] so that transcription levels would be consistent
between different transgenic lines, allowing direct comparison of
the toxicity of the two Ab forms. To maximize transcription levels,
transgenes inserted at chromosomal locations 86Fb and 96E were
recombined onto the same chromosome, giving TSpAb1–42rec and
Fig. 2. Ab produced with the Necrotic signal peptide gives dose-dependent neurodegenerative phenotypes. (A) Western blot analysis with duplicate lysate samples from:
ElavGal4-only control (lane 1); synthetic Ab1–40 (lane 2); 2  NSpAb1–42rec (lanes 3, 4); 2  TSpAb1–42rec (lanes 5, 6). Blot was probed with the W02 anti-Ab antibody and band
densities were quantiﬁed in the graph below. (B) RT-PCR showed that NSpAb1–42rec was transcribed at levels 1.3-fold higher than TSpAb1–42rec as quantiﬁed by densitometry of
the bands shown. (C) Expression of three different Ab transgenic constructs in the eye under GmrGAL4 control. Anterior is to the left. Compared to the GmrGAL4-only control, 2
copies of the original NSpAb1–42ori construct gives a strong rough eye phenotype; eye is smaller and ﬂatter than usual with disruption of the ommatidial array and black
necrotic spots. 2 copies of the NSpAb1–42rec construct gives only a mild rough-eye phenotype; eyes are slightly smaller than normal and some ommatidial disorganization is
seen, restricted to the posterior half of the eye. Expression of 2 copies of the TSpAb1–42rec construct results in an eye with no obvious morphological defects. Minimal variation
was observed within each genotype (N = 40) and the images here are representative of the typical severity for each construct. (D) Kaplan–Meier survival curves of various
genotypes of adult male ﬂies raised and maintained at 29 C. Pan-neuronal expression of NSpAb1–42 (ElavGal4 > NSpAb1–42ori and ElavGal4 > NSpAb1–42rec) causes a signiﬁcant
reduction (P < 0.0001 and P < 0.0001 respectively) in lifespan compared to ElavGal4>+ and +>NSpAb1–42ori/rec controls. (E) Negative geotaxis locomotor assay. Pan-neuronal
expression of NSpAb1–42ori under ElavGal4 control causes a signiﬁcant reduction in locomotor activity, as seen by lower average climbing score, at both 7 and 14 days post
eclosion (DPE, P < 0.001 and P < 0.001 respectively). Pan-neuronal expression of NSpAb1–42rec under ElavGal4 control causes a signiﬁcant reduction in locomotor activity at
both 14 and 21 DPE (P < 0.001 and P < 0.001 respectively).
K. Allan et al. / FEBS Letters 588 (2014) 3739–3743 3741
3742 K. Allan et al. / FEBS Letters 588 (2014) 3739–3743NSpAb1–42rec. Ab peptide expression with the NSpAb1–42rec construct
was 14 fold higher than with the TSpAb1–42rec chromosome
(Fig. 2A) while NSpAb1–42rec transcript levels were found to be
1.3 fold higher than TSpAb1–42rec levels using semi-quantitative
RT-PCR (Fig. 2B).
When expressed in the developing eye (Fig. 2C), two copies of
NSpAb1–42rec gave a mild rough eye phenotype compared to the
strong rough eye caused by NSpAb1–42ori whereas two copies of
TSpAb1–42rec gave a wild type eye phenotype. To further compare
the three transgenic lines, adult lifespan experiments were per-
formed (Fig. 2D). Pan-neuronal expression of the original NSpAb1–
42ori caused a dramatic decrease in longevity compared to control
strains. NSpAb1–42rec expression caused a milder but signiﬁcant
decrease in lifespan and TSpAb1–42rec had no discernible effect
(Fig. 2D). The same toxicity differential was observed in negative
geotaxis locomotor assays (Fig. 2E). NSpAb1–42ori performed the
worst; at 7 days post eclosion (DPE) these ﬂies already showed sig-
niﬁcantly diminished locomotor activity and at 14DPE they barely
moved. At 14DPE, the NSpAb1–42rec strain also showed signiﬁcantly
reduced negative geotaxis response and by 21DPE the response of
this strain was negligible. The TSpAb1–42rec strain showed no loco-
motor defects at any age-point.
4. Discussion
AD-like symptoms have been challenging to reproduce in Dro-
sophila due to the high levels of Ab peptide expression required
to produce convincing neurodegenerative phenotypes. Previous
research sought to maximize Ab toxicity through addition of signal
peptides [6–8]. Here, we demonstrate that one of the signal pep-
tides frequently used to generate secreted Ab, derived from the
ﬂy Necrotic protein, actually produces an aberrant Ab1–42 peptide
with an additional glutamine residue at the N-terminus, referred
to here as AbQ+1–42. A similar situation was seen with a C. elegans
Ab transgenic line that was shown to produce a truncated form
of Ab, Ab3–42 [30], which begins with glutamic acid. Using trans-
genic lines with equivalent transcription levels, we found that a
wild type Ab1–42 construct gave dramatically lower peptide levels
and no detectable neurodegenerative phenotypes compared to
the aberrant AbQ+1–42 form.
As we were unable to express sufﬁcient TSpAb1–42 to repeat the
mass spectrometry analysis performed on NSpAb1–42, we cannot
conﬁrm that TSpAb1–42 is being correctly processed. However,
Ab1–42 constructs using the pre-proenkephalin signal sequence
(also predicted to cleave correctly) are toxic when expressed at
high levels [7,15]. Therefore we propose that the addition of an
N-terminal glutamine enhances Ab abundance and therefore toxic-
ity compared to wild type Ab, a property revealed when the two
species are transcribed at similar levels.
The slightly higher NSpAbQ+1–42 transcript levels do not account
for the strong difference in peptide levels seen between the
NSpAb1–42 and TSpAb1–42 constructs. Possibly, NSpAbQ+1–42 is more
resistant to degradation and/or clearance. In the human AD brain,
N-terminally truncated Ab3–42 and Ab11–42 peptides represent
50% of total Ab found in senile plaques [33]. Both peptides begin
with a glutamic acid residue which can undergo post-translational
cyclization to produce pyroglutamate (pE) [34,35]. pE-modiﬁed Ab
displays increased stability due to reduced protease susceptibility
[33]. Glutamine can also undergo cyclization. We therefore
hypothesize that aberrant signal peptide cleavage from the
NSpAb1–42 construct results in a cyclized pQ form of Ab that dis-
plays greater stability and hence increased toxicity. Our ﬁndings
emphasize the importance of determining the species of Ab being
generated experimentally and the transcription levels of each dif-
ferent construct.Acknowledgements
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